The agreement between Evotec and the Crohn's & Colitis Foundation is directly related to Evotec's core business of drug discovery. This partnership could lead to significant advancements in IBD treatment, which would be a positive development for the company. The news is likely to be viewed favorably by investors, as it represents progress in expanding Evotec's pipeline and potential for future revenue. However, the actual impact on the stock will depend on the progress and success of the drug discovery efforts, which are inherently uncertain and typically take years to materialize.